Advertisement
Screener

FATE THERAPEUTICS INC (FATE) Increase (Decrease) in Accounts Payable and Accrued Liabilities

2.8 / 5 stars · 68/120 Roast Me

FATE THERAPEUTICS INC Increase (Decrease) in Accounts Payable and Accrued Liabilities

FATE THERAPEUTICS INC (FATE) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$4.52 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-13

  • FATE THERAPEUTICS INC increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $1.26M, a 159.50% increase year-over-year.
  • FATE THERAPEUTICS INC increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$5.77M.
  • FATE THERAPEUTICS INC increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $865.00K, a 32.06% increase year-over-year.
  • FATE THERAPEUTICS INC increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was -$550.00K, a 129.40% decline year-over-year.
  • FATE THERAPEUTICS INC increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was -$9.03M.
  • FATE THERAPEUTICS INC increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was -$1.66M.
  • FATE THERAPEUTICS INC increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was -$28.94M, a 303.06% decline from fiscal 2022.
  • FATE THERAPEUTICS INC increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $14.25M, a 141.27% increase from fiscal 2021.
Period endIncrease (Decrease) in Accounts Payable and Accrued Liabilities 3 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 6 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 9 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 12 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 77 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 80 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 83 month
2026-06-30$1.26M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
-$4.52M
10-Q · filed 2026-08-13
-$3.65M
derived: sum of 3 quarters · filed 2026-08-13
-$4.20M
derived: sum of 4 quarters · filed 2026-08-13
2026-03-31-$5.77M
10-Q · filed 2026-05-13
-$4.91M
derived: sum of 2 quarters · filed 2026-05-13
-$5.46M
derived: sum of 3 quarters · filed 2026-05-13
-$4.97M
derived: sum of 4 quarters · filed 2026-08-13
2025-12-31$865.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$315.00K
derived: sum of 2 quarters · filed 2026-02-26
$799.00K
derived: sum of 3 quarters · filed 2026-08-13
-$9.03M
10-K · filed 2026-02-26
2025-09-30-$550.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
-$66.00K
derived: sum of 2 quarters · filed 2026-08-13
-$9.89M
10-Q · filed 2025-11-13
-$9.24M
derived: sum of 4 quarters · filed 2026-08-13
2025-06-30$484.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
-$9.34M
10-Q · filed 2026-08-13
-$8.69M
derived: sum of 3 quarters · filed 2026-08-13
-$6.82M
derived: sum of 4 quarters · filed 2026-08-13
2025-03-31-$9.83M
10-Q · filed 2026-05-13
-$9.17M
derived: sum of 2 quarters · filed 2026-05-13
-$7.30M
derived: sum of 3 quarters · filed 2026-05-13
-$6.98M
derived: sum of 4 quarters · filed 2026-05-13
2024-12-31$655.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$2.53M
derived: sum of 2 quarters · filed 2026-02-26
$2.85M
derived: sum of 3 quarters · filed 2026-02-26
-$1.66M
10-K · filed 2026-02-26
2024-09-30$1.87M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
$2.19M
derived: sum of 2 quarters · filed 2025-11-13
-$2.32M
10-Q · filed 2025-11-13
-$4.21M
derived: sum of 4 quarters · filed 2025-11-13
2024-06-30$320.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12
-$4.19M
10-Q · filed 2025-08-12
-$6.08M
derived: sum of 3 quarters · filed 2025-08-12
-$8.36M
derived: sum of 4 quarters · filed 2025-08-12
2024-03-31-$4.51M
10-Q · filed 2025-05-13
-$6.40M
derived: sum of 2 quarters · filed 2025-05-13
-$8.68M
derived: sum of 3 quarters · filed 2025-05-13
-$13.05M
derived: sum of 4 quarters · filed 2025-05-13
2023-12-31-$1.89M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05
-$4.17M
derived: sum of 2 quarters · filed 2025-03-05
-$8.55M
derived: sum of 3 quarters · filed 2025-03-05
-$28.94M
10-K · filed 2025-03-05
2023-09-30-$2.28M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
-$6.65M
derived: sum of 2 quarters · filed 2024-11-12
-$27.05M
10-Q · filed 2024-11-12
-$23.66M
derived: sum of 4 quarters · filed 2024-11-12
2023-06-30-$4.37M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13
-$24.77M
10-Q · filed 2024-08-13
-$21.38M
derived: sum of 3 quarters · filed 2024-08-13
-$11.10M
derived: sum of 4 quarters · filed 2024-08-13
2023-03-31-$20.39M
10-Q · filed 2024-05-09
-$17.01M
derived: sum of 2 quarters · filed 2024-05-09
-$6.73M
derived: sum of 3 quarters · filed 2024-05-09
-$2.65M
derived: sum of 4 quarters · filed 2024-05-09
2022-12-31$3.39M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26
$13.67M
derived: sum of 2 quarters · filed 2024-02-26
$17.75M
derived: sum of 3 quarters · filed 2024-02-26
$14.25M
10-K · filed 2024-02-26
2022-09-30$10.28M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08
$14.36M
derived: sum of 2 quarters · filed 2023-11-08
$10.87M
10-Q · filed 2023-11-08
$485.00K
derived: sum of 4 quarters · filed 2023-11-08
2022-06-30$4.08M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08
$586.00K
10-Q · filed 2023-08-08
-$9.79M
derived: sum of 3 quarters · filed 2023-08-08
-$3.06M
derived: sum of 4 quarters · filed 2023-08-08
2022-03-31-$3.49M
10-Q · filed 2023-05-03
-$13.87M
derived: sum of 2 quarters · filed 2023-05-03
-$7.14M
derived: sum of 3 quarters · filed 2023-05-03
-$4.53M
derived: sum of 4 quarters · filed 2023-05-03
2021-12-31-$10.38M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28
-$3.64M
derived: sum of 2 quarters · filed 2023-02-28
-$1.04M
derived: sum of 3 quarters · filed 2023-02-28
$5.91M
10-K · filed 2023-02-28
2021-09-30$6.74M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03
$9.34M
derived: sum of 2 quarters · filed 2022-11-03
$16.29M
10-Q · filed 2022-11-03
$17.36M
derived: sum of 4 quarters · filed 2023-02-28
2021-06-30$2.61M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03
$9.55M
10-Q · filed 2022-08-03
$10.62M
derived: sum of 3 quarters · filed 2023-02-28
$3.19M
derived: sum of 4 quarters · filed 2023-02-28
2021-03-31$6.94M
10-Q · filed 2022-05-04
$8.02M
derived: sum of 2 quarters · filed 2023-02-28
$586.00K
derived: sum of 3 quarters · filed 2023-02-28
$8.71M
derived: sum of 4 quarters · filed 2023-02-28
2020-12-31$1.07M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28
-$6.36M
derived: sum of 2 quarters · filed 2023-02-28
$1.76M
derived: sum of 3 quarters · filed 2023-02-28
-$1.55M
10-K · filed 2023-02-28
2020-09-30-$7.43M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04
$690.00K
derived: sum of 2 quarters · filed 2021-11-04
-$2.63M
10-Q · filed 2021-11-04
-$1.11M
derived: sum of 4 quarters · filed 2022-02-28
2020-06-30$8.12M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04
$4.80M
10-Q · filed 2021-08-04
$6.32M
derived: sum of 3 quarters · filed 2022-02-28
$9.97M
derived: sum of 4 quarters · filed 2022-02-28
2020-03-31-$3.32M
10-Q · filed 2021-05-05
-$1.80M
derived: sum of 2 quarters · filed 2022-02-28
$1.85M
derived: sum of 3 quarters · filed 2022-02-28
$2.22M
derived: sum of 4 quarters · filed 2022-02-28
2019-12-31$1.51M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28
$5.17M
derived: sum of 2 quarters · filed 2022-02-28
$5.54M
derived: sum of 3 quarters · filed 2022-02-28
$4.28M
10-K · filed 2022-02-28
2019-09-30$3.66M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
$4.02M
derived: sum of 2 quarters · filed 2020-11-05
$2.77M
10-Q · filed 2020-11-05
$3.10M
derived: sum of 4 quarters · filed 2021-02-24
2019-06-30$365.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05
-$893.00K
10-Q · filed 2020-08-05
-$557.00K
derived: sum of 3 quarters · filed 2021-02-24
$618.00K
derived: sum of 4 quarters · filed 2021-02-24
2019-03-31-$1.26M
10-Q · filed 2020-05-11
-$922.00K
derived: sum of 2 quarters · filed 2021-02-24
$253.00K
derived: sum of 3 quarters · filed 2021-02-24
$2.32M
derived: sum of 4 quarters · filed 2021-02-24
2018-12-31$336.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24
$1.51M
derived: sum of 2 quarters · filed 2021-02-24
$3.58M
derived: sum of 3 quarters · filed 2021-02-24
$4.25M
10-K · filed 2021-02-24
2018-09-30$1.18M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05
$3.25M
derived: sum of 2 quarters · filed 2019-11-05
$3.92M
10-Q · filed 2019-11-05
$5.47M
derived: sum of 4 quarters · filed 2020-03-02
2018-06-30$2.07M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06
$2.74M
10-Q · filed 2019-08-06
$4.30M
derived: sum of 3 quarters · filed 2020-03-02
$4.11M
derived: sum of 4 quarters · filed 2020-03-02
2018-03-31$673.00K
10-Q · filed 2019-05-07
$2.23M
derived: sum of 2 quarters · filed 2020-03-02
$2.04M
derived: sum of 3 quarters · filed 2020-03-02
$1.51M
derived: sum of 4 quarters · filed 2020-03-02
2017-12-31$1.55M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02
$1.37M
derived: sum of 2 quarters · filed 2020-03-02
$834.00K
derived: sum of 3 quarters · filed 2020-03-02
$2.51M
10-K · filed 2020-03-02
2017-09-30-$184.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01
-$720.00K
derived: sum of 2 quarters · filed 2018-11-01
$957.00K
10-Q · filed 2018-11-01
$1.17M
derived: sum of 4 quarters · filed 2019-03-05
2017-06-30-$536.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06
$1.14M
10-Q · filed 2018-08-06
$1.36M
derived: sum of 3 quarters · filed 2019-03-05
$1.53M
derived: sum of 4 quarters · filed 2019-03-05
2017-03-31$1.68M
10-Q · filed 2018-05-10
$1.89M
derived: sum of 2 quarters · filed 2019-03-05
$2.07M
derived: sum of 3 quarters · filed 2019-03-05
$2.45M
derived: sum of 4 quarters · filed 2019-03-05
2016-12-31$217.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-05
$393.00K
derived: sum of 2 quarters · filed 2019-03-05
$771.00K
derived: sum of 3 quarters · filed 2019-03-05
$1.56M
10-K · filed 2019-03-05
2016-09-30$176.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01
$554.00K
derived: sum of 2 quarters · filed 2017-11-01
$1.34M
10-Q · filed 2017-11-01
$1.06M
derived: sum of 4 quarters · filed 2018-03-05
2016-06-30$378.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14
$1.17M
10-Q · filed 2017-08-14
$886.00K
derived: sum of 3 quarters · filed 2018-03-05
$789.00K
derived: sum of 4 quarters · filed 2018-03-05
2016-03-31$790.00K
10-Q · filed 2017-05-15
$508.00K
derived: sum of 2 quarters · filed 2018-03-05
$411.00K
derived: sum of 3 quarters · filed 2018-03-05
$998.00K
derived: sum of 4 quarters · filed 2018-03-05
2015-12-31-$282.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05
-$379.00K
derived: sum of 2 quarters · filed 2018-03-05
$208.00K
derived: sum of 3 quarters · filed 2018-03-05
$477.00K
10-K · filed 2018-03-05
2015-09-30-$97.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07
$490.00K
derived: sum of 2 quarters · filed 2016-11-07
$759.00K
10-Q · filed 2016-11-07
$686.00K
derived: sum of 4 quarters · filed 2017-03-16
2015-06-30$587.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08
$856.00K
10-Q · filed 2016-08-08
$783.00K
derived: sum of 3 quarters · filed 2017-03-16
$1.01M
derived: sum of 4 quarters · filed 2017-03-16
2015-03-31$269.00K
10-Q · filed 2016-05-09
$196.00K
derived: sum of 2 quarters · filed 2017-03-16
$424.00K
derived: sum of 3 quarters · filed 2017-03-16
$389.00K
derived: sum of 4 quarters · filed 2017-03-16
2014-12-31-$73.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16
$155.00K
derived: sum of 2 quarters · filed 2017-03-16
$120.00K
derived: sum of 3 quarters · filed 2017-03-16
$163.00K
10-K · filed 2017-03-16
2014-09-30$228.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-03
$193.00K
derived: sum of 2 quarters · filed 2015-11-03
$236.00K
10-Q · filed 2015-11-03
$464.00K
derived: sum of 4 quarters · filed 2016-03-03
2014-06-30-$35.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05
$8.00K
10-Q · filed 2015-08-05
$236.00K
derived: sum of 3 quarters · filed 2016-03-03
$794.00K
derived: sum of 4 quarters · filed 2016-03-03
2014-03-31$43.00K
10-Q · filed 2015-05-07
$271.00K
derived: sum of 2 quarters · filed 2016-03-03
$829.00K
derived: sum of 3 quarters · filed 2016-03-03
$2.34M
derived: sum of 4 quarters · filed 2016-03-03
$3.89M
10-Q · filed 2014-05-13
2013-12-31$228.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03
$786.00K
derived: sum of 2 quarters · filed 2016-03-03
$2.30M
derived: sum of 3 quarters · filed 2016-03-03
$1.58M
10-K · filed 2016-03-03
$3.85M
10-K · filed 2014-03-17
2013-09-30$558.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12
$2.07M
derived: sum of 2 quarters · filed 2014-11-12
$1.35M
10-Q · filed 2014-11-12
$2.12M
derived: sum of 4 quarters · filed 2015-03-12
$3.62M
10-Q · filed 2013-11-13
2013-06-30$1.51M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-12
$792.00K
10-Q · filed 2014-08-12
$1.56M
derived: sum of 3 quarters · filed 2015-03-12
2013-03-31-$719.00K
10-Q · filed 2014-05-13
$49.00K
derived: sum of 2 quarters · filed 2015-03-12
2012-12-31$768.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12
$405.00K
10-K · filed 2015-03-12
2012-09-30-$363.00K
10-Q · filed 2013-11-13
2011-12-31$134.00K
10-K · filed 2014-03-17

Similar stocks

Stock NameCountryMarket CapPE Ratio
Liminatus Pharma, Inc. (LIMN)United States$0.282B
Lexeo Therapeutics, Inc. (LXEO)United States$0.278B-4.19
PALISADE BIO, INC. (PALI)United States$0.275B-11.41
Invivyd, Inc. (IVVD)United States$0.270B-2.42
Inhibikase Therapeutics, Inc. (IKT)United States$0.296B-4.44
X4 Pharmaceuticals, Inc (XFOR)United States$0.297B-4.99
SUTRO BIOPHARMA, INC. (STRO)United States$0.260B-3.05
SAB Biotherapeutics, Inc. (SABS)United States$0.306B-25.49
Century Therapeutics, Inc. (IPSC)United States$0.306B-4.02
Lineage Cell Therapeutics, Inc. (LCTX)United States$0.241B-10.35